selank mastery course
Unit 5 of 11
immune modulation
IL-6 regulation and the tuftsin heritage
the immune thread
selank's origin from tuftsin left it with genuine immunomodulatory properties. it regulates IL-6 expression, enhances innate immune function, and shows anti-inflammatory effects. this is unusual for an anxiolytic and reflects its unique peptide lineage.
selank's immune properties come directly from its tuftsin heritage. most anxiolytics have no meaningful immune activity -- selank's dual profile is a direct consequence of its peptide design origin.
immune modulation snapshot
direction and targets selank influences in immune-related studies.
IL-6
bidirectional regulation -- normalized rather than simply suppressed
phagocytosis
enhanced, inherited from tuftsin parent peptide
T-cells
modulation of T-helper cell balance (Th1/Th2)
IFN-alpha
interferon-alpha induction reported in cell culture studies
cytokine response across dose
drag the dose slider to see how three rodent-model cytokine endpoints shift relative to baseline. directions reflect the bidirectional pattern described above (pro-inflammatory down, IL-6 normalized, anti-inflammatory up).
selank dose -> cytokine response
center line = baseline. values are illustrative of the rodent / cell-culture immunomodulator pattern (Uchakina et al. 2008, Ershov et al. 2009) -- not absolute concentrations.
interactive explorer
explore the key concepts for this unit.
cytokine balance dashboard
key terms
definitions you will encounter throughout this unit.
I
interleukin-6 -- a cytokine (signaling protein) with both pro-inflammatory and anti-inflammatory roles. unlike simple pro-inflammatory cytokines, IL-6 can promote or resolve inflammation depending on context. selank appears to normalize IL-6 levels rather than simply suppressing them, which is consistent with its classification as an immunomodulator.
C
a small signaling protein released by cells to coordinate immune responses. pro-inflammatory cytokines (TNF-alpha, IL-1beta) amplify inflammation. anti-inflammatory cytokines (IL-10, TGF-beta) resolve it. immunomodulators like selank adjust the balance between these opposing signals rather than pushing strongly in one direction.
I
the body's first line of immune defense -- rapid, non-specific responses that activate within hours. includes physical barriers (skin, mucus), phagocytes (cells that engulf pathogens), and natural killer cells. tuftsin and selank primarily enhance this branch of immunity through improved phagocytic activity.
A
the slower, highly specific branch of immunity. T-cells and B-cells learn to recognize specific pathogens and create memory for future encounters. selank's influence on T-helper cell balance (Th1 vs Th2) connects it to adaptive immunity, though this effect is less well-characterized than its innate immune actions.
I
adjusting the immune system's activity up or down depending on what the body needs. this is different from immunosuppression (always dampening immunity) or immunostimulation (always boosting it). selank is classified as an immunomodulator because it can enhance weak immune responses and dampen excessive ones.
I
a signaling protein produced by immune cells in response to viral infection. IFN-alpha triggers antiviral defense mechanisms in neighboring cells. selank has been reported to induce IFN-alpha production in cell culture, suggesting possible antiviral properties -- though this has not been tested in human viral infection studies.
how selank modulates immunity without suppressing it -- the simple version
a plain-English walkthrough of bidirectional immune regulation.
most drugs that affect the immune system push it in one direction -- either ramping it up (immunostimulants) or dampening it down (immunosuppressants like corticosteroids). selank does something unusual: it acts as an immunomodulator (a substance that adjusts the immune system toward balance rather than forcing it one way). when the immune system is underactive, selank appears to boost it -- enhancing phagocytosis (the process where immune cells eat and destroy invaders) and increasing interferon production (proteins that help fight viruses). when the immune system is overactive (as in chronic inflammation), selank appears to dial it back by normalizing cytokine levels (the signaling proteins that coordinate immune responses). this bidirectional behavior comes directly from its tuftsin heritage -- tuftsin itself is a natural immune regulator, not a simple on/off switch.
A
the immune system uses two major T-helper cell subtypes to coordinate different types of defense. Th1 cells drive cell-mediated immunity (fighting viruses and intracellular bacteria) by producing cytokines like IFN-gamma (interferon-gamma) and IL-2 (interleukin-2). Th2 cells drive humoral immunity (fighting parasites and producing antibodies) by releasing IL-4, IL-5, and IL-13. an imbalance toward Th1 is associated with autoimmune diseases (the body attacking itself), while a Th2 skew is linked to allergies and asthma. selank has been shown to influence the Th1/Th2 ratio in animal models, generally pushing toward balance rather than favoring either arm. the specific cytokine shifts depend on the starting immune state -- in Th1-dominant conditions, selank can reduce pro-inflammatory cytokines, while in Th2-dominant states, it can upregulate Th1 markers.
advanced: gene expression in immunocytes
studies examining selank's effect on immune cell gene expression found changes in 84 genes related to immune function. these included upregulation of genes encoding chemokines (small proteins that guide immune cells to infection sites), cytokines involved in both innate and adaptive immunity, and receptors that control immune cell activation. notably, selank altered expression of genes in the IL-6 signaling pathway -- both the cytokine itself and its receptor components -- which is consistent with the bidirectional IL-6 regulation observed at the protein level. this gene-level data suggests selank's immune effects are not a secondary side effect of its CNS activity but a genuine, programmed response inherited from its tuftsin parent sequence.
advanced: immunomodulator vs immunosuppressant
the distinction between immunomodulation and immunosuppression is clinically critical. immunosuppressants (like prednisone or cyclosporine) broadly reduce immune function -- they work for autoimmune diseases and transplant rejection but leave patients vulnerable to infections and cancer. immunomodulators (like selank, thymosin alpha-1, or low-dose naltrexone) adjust immune function contextually -- they restore balance without creating blanket suppression. selank's tuftsin backbone gives it phagocytosis-enhancing properties (innate immune boost) while its regulatory peptide effects normalize cytokine signaling. this means selank theoretically should not increase infection risk the way corticosteroids do. however, this distinction has been established primarily in cell culture and animal models -- no human study has directly compared selank's infection risk profile to established immunosuppressants.
where this has been studied
evidence from published research -- mostly in-vitro and animal models from Russian laboratories.
cytokine modulation
Uchakina and colleagues demonstrated that selank modulated IL-6 (interleukin-6) expression bidirectionally in human blood cell cultures. when IL-6 was elevated (simulating inflammation), selank reduced it. when IL-6 was at baseline, selank either maintained or slightly increased it. this pattern -- normalization rather than one-directional change -- is the hallmark of a true immunomodulator.
gene expression profiling
microarray analysis of human immune cells treated with selank revealed expression changes across 84 immune-related genes. the affected genes spanned chemokine signaling, cytokine production, and immune cell activation pathways. these broad changes suggest selank reprograms immune cell behavior at the transcriptional level rather than simply blocking individual molecules.
phagocytosis enhancement
building on tuftsin's established role as a phagocytosis stimulant, selank was shown to enhance the ability of macrophages (immune cells that engulf pathogens) to destroy bacteria in culture. this effect was dose-dependent and stronger than tuftsin alone -- likely because selank's extended half-life allows more sustained receptor activation compared to the rapidly degraded parent peptide.
autoimmune model research
in rodent models of autoimmune-like inflammation, selank reduced markers of excessive immune activation without impairing the animals' ability to fight infection. this supports the immunomodulator classification -- the peptide calmed overactive immunity while preserving normal defense functions. however, these are animal models of induced inflammation, not naturally occurring human autoimmune diseases.
selank vs common immune modulators
how selank's immune profile compares to established immunotherapies.
selank
- bidirectional: normalizes both overactive and underactive immunity
- enhances phagocytosis (inherited from tuftsin parent)
- induces interferon-alpha in cell culture
- no reported immunosuppressive side effects
- evidence limited to animal models and in-vitro studies
corticosteroids
- unidirectional: broadly suppresses immune function
- reduces inflammation rapidly and effectively
- increases infection risk with prolonged use
- side effects: weight gain, bone loss, glucose dysregulation
- decades of human clinical data; FDA-approved for many conditions
biologics (TNF inhibitors)
- targeted: block specific cytokines (TNF-alpha, IL-6, etc.)
- highly effective for autoimmune conditions (RA, Crohn's, psoriasis)
- increased infection risk (especially tuberculosis reactivation)
- expensive ($20,000-$50,000+/year) and require injection
- extensive clinical trial evidence and FDA approval
dose and species matter: immune effects observed at research doses in animal models may not translate directly to the doses and routes used in human anxiolytic protocols. the immune modulation profile is real but its clinical significance at standard anxiolytic doses remains unclear.